PDS Biotechnology Corporation – Trademark Portfolio
Entity Type: 03
PDS Biotechnology Corporation holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include VERSAMUNE, INFECTIMUNE, and PDS BIOTECHNOLOGY. The owner is based in Cincinnati, OH.
3130 Highland Avenue, Third Floor
Cincinnati, OH 45219
Showing of trademarks Trademarks
Trademark Classifications
PDS Biotechnology Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 abandoned.
What trademark classes does PDS Biotechnology Corporation file in?
PDS Biotechnology Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are PDS Biotechnology Corporation's most well-known trademarks?
PDS Biotechnology Corporation's registered trademark portfolio includes well-known marks such as VERSAMUNE, INFECTIMUNE, and PDS BIOTECHNOLOGY. These are among 4 currently registered trademarks in the portfolio.
What is PDS Biotechnology Corporation's trademark registration success rate?
PDS Biotechnology Corporation has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.